Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel

Yuqi Xing, Ruiqi Zhong, Qianchen Li, Xinwei Duan, Moyang Xu, Miao Yu, Chenying Liu, Junming He, Yi Sun, Yunling Wang, Xiaojing Guo, Yunfei Xu, Hongnan Mo, Fei Ma, Xiang Li, Jun ZhanNature Communications 2026 · DOI

Abstract

Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined. Here, based on a meta-analysis, we first show that treatment with nab-paclitaxel results in a higher overall response rate and pathological complete response compared to paclitaxel in female patients with breast cancer. Notably, TREM2 expression in macrophages is elevated in primary tumors of paclitaxel- but not nab-paclitaxel-treated female patients. In metastatic breast cancer, TREM2+ macrophage infiltration is increased in primary tumors. In breast cancer models in female mice, paclitaxel, but not nab-paclitaxel, promotes lung metastasis by recruiting TREM2+ macrophages to primary tumors. Mechanistically, paclitaxel enhances the ATF3-FGF2 axis in breast cancer cells; secreted FGF2 activates the EGR1-TREM2-EMT cytokine axis in macrophages. Genetic ablation of Trem2 or pharmacologic targeting with antisense oligonucleotides suppress paclitaxel-induced breast cancer lung metastasis in vivo. Collectively, our findings demonstrate that paclitaxel, but not nab-paclitaxel, stimulates TREM2 expression and expands TREM2+ macrophages, suggesting that TREM2 targeting could enhance paclitaxel efficacy while limiting metastasis.

Introduction

Taxanes, specifically paclitaxel (PTX) and nanoparticle albumin-bound paclitaxel (Nab-PTX), are cornerstone chemotherapies for breast cancer. While both drugs function by stabilizing microtubules to inhibit mitosis, clinical evidence has increasingly suggested that Nab-PTX yields superior patient outcomes. Conversely, PTX has been paradoxically linked to the promotion of an immunosuppressive tumor microenvironment and increased lung metastasis. This study investigates the molecular basis for these divergent clinical profiles, focusing on how PTX actively reshapes the immune landscape through the expansion of specific macrophage populations.

Methodology

The researchers employed a multi-disciplinary approach to dissect the differential effects of PTX and Nab-PTX:

  • Clinical Meta-analysis: Data from 17 clinical studies involving 6,486 patients were pooled to compare Objective Response Rate (ORR) and Pathological Complete Response (pCR).
  • Multi-omics Profiling: Single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and ATAC-seq were used to track macrophage populations and chromatin accessibility changes in both human patient samples and mouse models.
  • In Vivo Modeling: Orthotopic breast cancer models (4T1, Py8119) were utilized in wild-type and Trem2 knockout mice. Pharmacological targeting of TREM2 was achieved using Antisense Oligonucleotides (ASOs).
  • In Vitro Signaling Assays: Conditioned media swaps, ChIP-qPCR, and luciferase reporter assays were used to map the cancer-to-macrophage signaling axis.

Results and Discussion

The Clinical Efficacy Gap

The meta-analysis confirmed the clinical superiority of Nab-PTX, which showed a 42% higher odds of ORR (OR 1.42) and a 69% higher odds of pCR (OR 1.69) compared to PTX. This discrepancy suggested that PTX might be triggering biological processes that counteract its primary cytotoxic effects.

PTX-Induced Metastasis via TREM2+ Macrophages

In mouse models, while both PTX and Nab-PTX effectively reduced primary tumor size, PTX treatment significantly increased the burden of lung metastasis. Crucially, this pro-metastatic effect was entirely absent in Trem2 knockout mice. Further analysis revealed that PTX, but not Nab-PTX, drives the expansion of TREM2+ macrophages within the primary tumor. These macrophages were found to secrete a cocktail of cytokines, most notably Serpin E1, which triggers the Epithelial-Mesenchymal Transition (EMT) in cancer cells, facilitating their migration to the lungs.

The ATF3-FGF2-EGR1-TREM2 Signaling Axis

Mechanistic investigations revealed a complex paracrine signaling loop initiated by PTX. PTX treatment increases chromatin accessibility at the ATF3 locus in cancer cells, leading to the upregulation of ATF3 and the subsequent secretion of FGF2. This secreted FGF2 acts on nearby macrophages, activating the ERK1/2-EGR1 pathway, which directly drives the expression of TREM2. This specific axis explains why PTX, but not Nab-PTX, expands this pro-metastatic immune population.

Therapeutic Rescue with ASOs

To test the clinical potential of these findings, researchers co-administered PTX with Trem2-targeting ASOs. This combination therapy successfully abrogated PTX-induced lung metastasis and extended overall survival in mice without overt organ toxicity. This suggests that targeting TREM2 can uncouple the cytotoxic benefits of PTX from its dangerous side effects, potentially turning a flawed monotherapy into a highly effective combination strategy.

Limitations and Future Directions

While this study identifies a robust mechanism for PTX-induced lung metastasis, several questions remain. The research focused primarily on the lungs; whether the TREM2-driven mechanism applies to other common metastatic sites like the bone, liver, or brain requires further investigation. Additionally, while FGF2 was identified as a major driver, cytokine arrays suggested other factors (such as GDF15) might also play a role. Future clinical translation will require optimizing ASO delivery and identifying the patient cohorts most likely to benefit from TREM2-targeted interventions.

Summary updated

Abstract

Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined. Here, based on a meta-analysis, we first show that treatment with nab-paclitaxel results in a higher overall response rate and pathological complete response compared to paclitaxel in female patients with breast cancer. Notably, TREM2 expression in macrophages is elevated in primary tumors of paclitaxel- but not nab-paclitaxel-treated female patients. In metastatic breast cancer, TREM2<sup>+</sup> macrophage infiltration is increased in primary tumors. In breast cancer models in female mice, paclitaxel, but not nab-paclitaxel, promotes lung metastasis by recruiting TREM2<sup>+</sup> macrophages to primary tumors. Mechanistically, paclitaxel enhances the ATF3-FGF2 axis in breast cancer cells; secreted FGF2 activates the EGR1-TREM2-EMT cytokine axis in macrophages. Genetic ablation of Trem2 or pharmacologic targeting with antisense oligonucleotides suppress paclitaxel-induced breast cancer lung metastasis in vivo. Collectively, our findings demonstrate that paclitaxel, but not nab-paclitaxel, stimulates TREM2 expression and expands TREM2<sup>+</sup> macrophages, suggesting that TREM2 targeting could enhance paclitaxel efficacy while limiting metastasis.
BibTeX
@inproceedings{xing2026paclitaxel,
  author = {Yuqi Xing and Ruiqi Zhong and Qianchen Li and Xinwei Duan and Moyang Xu and Miao Yu and Chenying Liu and Junming He and Yi Sun and Yunling Wang and Xiaojing Guo and Yunfei Xu and Hongnan Mo and Fei Ma and Xiang Li and Jun Zhan},
  title = {{Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel}},
  booktitle = {Nature Communications},
  year = {2026},
  doi = {10.1038/s41467-026-69060-5},
}
Figure